Search results for: Anti-
#32475078 
2020/05/31
To Up
Latent class trajectory modelling of 2-components-DAS28 identifies multiple rheumatoid arthritis phenotypes of response to biologic disease modifying anti-rheumatic drugs.
To determine whether using a re-weighted disease activity score that better reflects joint synovitis, the 2-component DAS28 (2C-DAS28), based on 28-swollen joint count and C-reactive protein, produces more clinically relevant treatment outcome trajectories compared with the standard 4 component DAS28 (4C-DAS28).Arianna Dagliati, Darren Plant, Nisha Nair, Meghna Jani, Beatrice Amico, Niels Peek, Ann W Morgan, John Isaacs, Anthony G Wilson, Kimme L Hyrich, Nophar Geifman, Anne Barton,
1080 related Products with: Latent class trajectory modelling of 2-components-DAS28 identifies multiple rheumatoid arthritis phenotypes of response to biologic disease modifying anti-rheumatic drugs.
1 mg500 0.1 mg0.1ml (1.3mg/ml)0.1 mg100 μg100 0.1 mg250
Related Pathways
#32475053 2020/05/31
To Up
Reply.
We are pleased to respond to the commentary by Dr. Chao Cheng and colleagues on our recent publication entitled "Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Association between Osteoarthritis and Cardiovascular Diseases: A Longitudinal Study" that was published in Arthritis & Rheumatology in November 2019 (1). The commentary raises important issues about further exploring the characteristics of our study population (the elderly) in whom it is well known that both the chronic conditions of OA and CVD are more prevalent.Mohammad Atiquzzaman, Mohammad Ehsanul Karim, Jacek Kopec, Hubert Wong, Aslam H Anis
1312 related Products with: Reply.
Related Pathways
#32475043 2020/05/31
To Up
Lower urinary α-Klotho is associated with lower angiotensin-(1-7) and higher blood pressure in young adults born preterm with very low birthweight.
Early-life factors including preterm birth and VLBW increase the risk of hypertension, but the mechanisms remain poorly understood. Reductions in the anti-aging protein α-klotho are associated with hypertension, possibly due to angiotensin (Ang) II activation, but the mechanisms are incompletely understood and clinical evidence is lacking. The association of α-klotho with the alternative Ang-(1-7) pathway, which counteracts Ang II to lower BP, is undescribed. We hypothesized that lower urinary α-klotho is associated with higher BP and lower urinary Ang-(1-7) in preterm-born VLBW young adults. In a cross-sectional analysis of data from a prospective cohort of 141 preterm-born VLBW young adults, we assessed the associations among urinary α-klotho/creatinine, Ang II/creatinine, Ang-(1-7)/creatinine, Ang II/Ang-(1-7), and BP using generalized linear models adjusted for age and hypertensive pregnancy and conducted a sensitivity analysis in 32 term-born young adults. Among those born preterm, lower α-klotho/creatinine was associated with higher systolic BP (adjusted β (aβ): -2.58 mm Hg, 95% CI -4.99 to -0.17), lower Ang-(1-7)/creatinine (ln aβ: 0.1, 0.04-0.16), and higher Ang II/Ang-(1-7) (ln aβ: -0.14, -0.21 to -0.07). In term-born participants, α-klotho/creatinine was inversely associated with Ang II/creatinine (ln aβ: -0.15, -0.27 to -0.03) and Ang II/Ang-(1-7) (ln aβ: -0.15, -0.27 to -0.03). In preterm-born young adults with VLBW, lower urinary α-klotho/creatinine was associated with higher SBP, lower urinary Ang-(1-7)/creatinine, and higher urinary Ang II/Ang-(1-7). Reduced renal α-klotho expression could lead to renal Ang-(1-7) suppression as a novel mechanism for the development of hypertension among individuals born preterm with VLBW.Andrew M South, Hossam A Shaltout, TanYa M Gwathmey, Elizabeth T Jensen, Patricia A Nixon, Debra I Diz, Mark C Chappell, Lisa K Washburn
2384 related Products with: Lower urinary α-Klotho is associated with lower angiotensin-(1-7) and higher blood pressure in young adults born preterm with very low birthweight.
100ug Lyophilized1mg100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized
Related Pathways
#32475041 2020/05/30
To Up
Potential role of Anti-IL-17 in COVID-19 treatment.
Erhan Ayhan, Murat Öztürk, İsa An, Ayman Abdelmaksoud, Eşref Araç
1251 related Products with: Potential role of Anti-IL-17 in COVID-19 treatment.
100 UG100 μg100 μg100.00 ug100.00 ug100 μg100ug Lyophilized100ug0.1ml100 μg100 μg100 μg
Related Pathways
-
No related Items
#32475025 2020/05/31
To Up
Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns among Medicaid and Medicaid-Medicare Dually Eligible in Puerto Rico.
Estimate the prevalence of rheumatoid arthritis (RA) in Puerto Rico and describe disease-modifying anti-rheumatic drug (DMARD) dispensing patterns by prescriber specialty. Illustrate the impact of RA case definition on the estimated prevalence.José J Hernández-Muñoz, Wenfei Wei, Radames Sierra-Zorita
2731 related Products with: Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns among Medicaid and Medicaid-Medicare Dually Eligible in Puerto Rico.
25 mg2.5 mg96T100ul50 mg10 mg100 assays1000 tests50 ug 100ug25 mg100 assays
Related Pathways
#32475023 2020/05/31
To Up
Ex vivo and in vivo studies of Viola tricolor Linn. as potential cardio protective and hypotensive agent: Inhibition of voltage-gated Ca ion channels.
VFatima Saqib, Khizra Mujahid, Muhammad Arif Aslam, Alotaibi Modhi, Marius Alexandru Moga, Elena Bobescu, Luigi Marceanu
2392 related Products with: Ex vivo and in vivo studies of Viola tricolor Linn. as potential cardio protective and hypotensive agent: Inhibition of voltage-gated Ca ion channels.
48 samples100 assays96 assays 100 assays 50 UG100 assays48 assays 0.5mg100 assays
Related Pathways
-
No related Items
#32475020 2020/05/31
To Up
First cases of ustekinumab-induced spondylodiscitis and scaroiliitis in patients with psoriasis successfully treated with pentoxyfilline.
Charbel Skayem, Nakhle Ayoub
2623 related Products with: First cases of ustekinumab-induced spondylodiscitis and scaroiliitis in patients with psoriasis successfully treated with pentoxyfilline.
Related Pathways
-
No related Items
#32475019 2020/05/31
To Up
Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.
Since December 2019, a novel coronavirus (SARS-CoV-2) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The anti-retroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1600 mg of FPV twice daily on Day 1, followed by 600 mg twice daily from Day 2 to Day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 h) concentrations of most samples were lower than the lower limit of quantification (1 µg/mL) and EC (9.7 µg/mL) against SARS-CoV-2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19.Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Keisuke Tomii, Tohru Hashida
2848 related Products with: Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.
100 μg10mg100 μg20 mg0.1ml100 ug1g 96T100 ug
Related Pathways
#32475009 2020/05/31
To Up
Safety and tolerability of subcutaneous methotrexate in routine clinical practice.
To show safety and efficacy of subcutaneous (sc) methotrexate (MTX) compared to oral MTX, alternative disease-modifying anti-rheumatic drugs (DMARD) monotherapy, and combinations (biologic monotherapy, conventional and biologic combination groups) in routine clinical practice.Christien Kh Li, Kenneth Baker, Tania Jones, Elizabeth Coulson, Andrew Roberts, Fraser Birrell